Personalis to Participate in the BTIG 13th Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference

On January 28, 2026 Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, reported that its management team will be attending the BTIG 13th Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference on Wednesday, February 11, 2026 at the Cliff Lodge in Snowbird, UT.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

(Press release, Personalis, JAN 28, 2026, View Source [SID1234662340])

Halozyme Raises 2025 Revenue Estimates,
Raises 2026 and Multi-Year Financial Guidance

On January 28, 2026 Halozyme Therapeutics, Inc. (Nasdaq: HALO) ("Halozyme" or the "Company") reported a business update, including providing preliminary unaudited 2025 revenue estimates and raising full year 2026 and multi-year financial guidance. The Company also announced it acquired Surf Bio, Inc. ("Surf Bio"), a biopharmaceutical company with an innovative, biologic hyperconcentration technology seeking to transform the delivery of antibodies and biologics, in December 2025.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"Our increased multi-year guidance reflects both the strength of our core ENHANZE business and the exceptional momentum we built in 2025. In 2025, we expect royalty revenue growth to exceed 50% year‑over‑year, a clear demonstration of the strength of our business model and the durable demand for ENHANZE‑enabled products globally. In parallel, we significantly expanded new partnerships, signing three new ENHANZE collaboration and licensing agreements, one new auto-injector commercial licensing and supply agreement and two auto-injector development agreements. In addition, our partner Janssen gained global approvals for Rybrevant Faspro, the tenth ENHANZE-approved product. During 2025, we advanced our strategic growth roadmap with the acquisitions of Elektrofi and their Hypercon technology and of Surf Bio and their hyperconcentration technology. Both hyperconcentration technologies have long-duration IP into the mid-2040s. Our operational accomplishments and acquisitions broaden our drug delivery portfolio and opportunity, amplify and extend our royalty horizons, and diversify the pathways through which we create value," said Dr. Helen Torley, President and Chief Executive Officer.

Dr. Torley added, "In the near-term, our strong 2026 total revenue expectations of 23% to 30% year‑over‑year growth underscore the strength of our royalty revenue, which is projected to exceed $1 billion in 2026, growing at 30% to 35% versus prior year. This is one year earlier than previously projected. By the end of 2026, we project we will have 15 partner programs in development and have signed three or more new drug delivery licensing agreements, expanding the reach and growing our opportunity through our diversified drug delivery portfolio. Taken together, these drivers reinforce our confidence in delivering durable revenue growth well into the 2040s and support our conviction in Halozyme’s long‑term growth profile which will deliver sustained value for shareholders."
The Company acquired Surf Bio for an upfront payment of $300 million, subject to customary purchase price adjustments, and up to $100 million milestone payments contingent on product development and regulatory approval milestones, for a total consideration of up to $400 million.
The Surf Bio hyperconcentration technology is being developed to enable high concentrations of up to 500 mg/mL across a wide range of therapeutics, including monoclonal antibodies and small molecules, for delivery in a single auto-injector shot for at-home or in-HCP office use. These high concentration formulations are achievable using Surf Bio’s proprietary, protective excipient and spray dry approach, enabling accessible and patient-friendly subcutaneous delivery of antibodies and biologics.

Table 1. 2025 Unaudited Preliminary Revenue Estimates for the Twelve Months Ended December 31, 2025

2025 Estimate
Expected YoY Growth1
Total Revenue $1,385 to $1,400 million 36% to 38%
Royalty Revenue $865 to $870 million 51% to 52%

Financial Outlook for 2026
The Company is raising its financial guidance for 2026. For the full year 2026, the Company expects:

•Total revenue of $1,710 million to $1,810 million, representing growth of 23% to 30% over projected 2025 total revenue, primarily driven by increases in royalty revenue and product sales from API.
•Revenue from royalties of $1,130 million to $1,170 million, representing growth of 30% to 35% over 2025.
•Adjusted EBITDA of $1,125 million to $1,205 million, including new Hypercon and Surf Bio investment of approximately $60 million, which was not included in prior 2026 guidance.
•Non-GAAP diluted earnings per share of $7.75 to $8.25. The Company’s earnings per share guidance includes new Hypercon and Surf Bio investment of approximately $60 million not included in prior 2026 guidance and does not consider the impact of potential future share repurchases.

Table 2. 2026 Financial Guidance

Previous Guidance Range New Guidance Range
Expected YoY Growth2
Total Revenue $1,430 to $1,530 million
$1,710 to $1,810 million
23% to 30%
Royalty Revenue $900 to $940 million $1,130 to $1,170 million 30% to 35%
Adjusted EBITDA $1,000 to $1,080 million $1,125 to $1,205 million ——
Non-GAAP Diluted EPS $6.50 to $7.00 $7.75 to $8.25 ——

Footnotes:
1 Growth rates calculated from 2024 actual to low end of 2025 range and high-end of 2025 range.
2 Growth rates calculated from 2025 midpoint to low end of 2026 range and high-end of 2026 range.
3 Adjusted EBITDA and Non-GAAP Diluted EPS are Non-GAAP financial measures. See "Note Regarding Use of Non-GAAP Financial Measures" below for an explanation of these measures.
4 Including investment of approximately $60 million for Hypercon and Surf Bio not included in prior 2026 guidance.

Webcast and Conference Call
Halozyme will host an Investor Conference Call today, Wednesday, January 28 at 5:30am PT/8:30am ET. Pre-registration of the live call can be accessed via link here: View Source A webcast of the live call and presentation materials will be available through the "Investors" section of Halozyme’s corporate website at ir.halozyme.com.

(Press release, Halozyme, JAN 28, 2026, View Source [SID1234662325])

Taiho Oncology Appoints Peter Melnyk as President & Chief Executive Officer

On January 28, 2026 Taiho Oncology, Inc., a company developing and commercializing novel treatments for hematologic malignancies and solid tumors, reported that Peter Melnyk has been appointed to President & Chief Executive Officer, effective immediately. Mr. Melnyk succeeds Tim Whitten, who has retired after 13 years of service.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"Peter has spent his career working to bring transformative oncology treatments to patients around the world," said Masa Kobayashi, President & Representative Director of Taiho Pharmaceutical Co., Ltd. "With Peter as President & CEO, we are positioning the company for a successful future to help as many people affected by cancer as possible. We trust Peter to guide TOI’s continued growth and innovation as we pursue our mission to improve the lives of patients with cancer, their families and their caregivers."

"During Tim Whitten’s tenure, TOI launched its first commercial product and has grown from one product in one indication to three products in five indications with a robust pipeline and a bright future," Mr. Kobayashi continued. "The Taiho organization has deep gratitude for Tim’s strong, compassionate leadership and the positive impact that he has made – both within the company and more broadly, in oncology. We thank him for the positive impact he has had on the lives of patients with cancer and wish him well in his retirement."

Mr. Melnyk has more than 30 years of proven experience in oncology commercialization and leadership across pharmaceuticals, medical devices and biotech sectors. Mr. Melnyk joined Taiho Oncology from Alpha Tau Medical, where he was the Chief Commercial Officer and former board member and led the global commercialization efforts for a novel alpha-emitting radiotherapeutic. He was also the CEO of Fortovia Therapeutics and drove the transformation and portfolio expansion in oncology supportive care. In addition, Mr. Melnyk was the Chief Commercial Officer at Novocure, where he built the global commercial infrastructure and launched Optune, a novel medical device for the treatment of glioblastoma.

"I’m deeply honored to be part of Taiho’s next chapter and with my colleagues, continue making a lasting impact for the patients we serve," Mr. Melnyk said. "Together, we will continue to build upon Taiho Oncology’s strong foundation – combining rigorous science, strategic thinking and heartfelt dedication to patients. Thank you to every Taiho team member for your continued commitment to patients and innovation."

(Press release, Taiho, JAN 28, 2026, View Source [SID1234662341])

Immix Biopharma Receives U.S. FDA Breakthrough Therapy Designation for NXC-201

On January 28, 2026 Immix Biopharma, Inc. ("ImmixBio", "Company", "We" or "Us" or "IMMX"), the global leader in relapsed/refractory AL Amyloidosis, reported that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to NXC-201 for the treatment of relapsed/refractory AL Amyloidosis.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Per FDA, Breakthrough Therapy designation aims to expedite the development and review of drugs that are intended to treat a serious condition and preliminary clinical evidence indicates that the drug may demonstrate substantial improvement over available therapy on a clinically significant endpoint.

The FDA Breakthrough Therapy designation is based on Phase 2 NXC-201 interim clinical results from the NEXICART-2 clinical trial, presented December 7, 2025 in an oral presentation at the American Society of Hematology (ASH) (Free ASH Whitepaper) annual meeting in Orlando, FL.

"We are grateful to FDA for recognizing NXC-201 as the only granted FDA Breakthrough Designation for a therapy in active development in relapsed/refractory AL Amyloidosis, where no approved therapies exist for patients today," said Ilya Rachman, MD, PhD, Chief Executive Officer of Immix Biopharma. Gabriel Morris, Chief Financial Officer of Immix Biopharma, added, "We are looking forward to completing enrollment of NEXICART-2 with the goal of delivering this promising therapy to patients upon planned BLA submission this year."

About NEXICART-2
NEXICART-2 (NCT06097832) is an ongoing multi-site U.S. Phase 2 clinical trial of sterically-optimized CAR-T NXC-201 in relapsed/refractory AL Amyloidosis, with a registrational design. NEXICART-2 is expected to enroll 40 patients.

About AL Amyloidosis
AL amyloidosis is a devastating disease where the immune system, that’s supposed to protect, instead continuously produces toxic light chains, clogging up the heart, kidney and liver, causing organ failure and death.

The number of patients in the U.S. with relapsed/refractory AL Amyloidosis is estimated to be growing at 12% per year according to Staron, et al Blood Cancer Journal, to approximately 38,500 patients in 2026.

The Amyloidosis market was $3.6 billion in 2017, and is expected to reach $6 billion in 2025, according to Grand View Research.

About NXC-201
NXC-201 is a sterically-optimized BCMA-targeted chimeric antigen receptor T (CAR-T) cell therapy with a "digital filter" that is designed to filter out non-specific activation. NXC-201 teaches the immune system to recognize and eliminate the source of the toxic light chains. NXC-201 has been awarded Breakthrough Therapy Designation (BTD) and Regenerative Medicine Advanced Therapy (RMAT) by the FDA, and Orphan Drug Designation (ODD) by the US FDA and in the EU by the EMA.

(Press release, Immix Biopharma, JAN 28, 2026, View Source [SID1234662326])

Accent Therapeutics to Utilize Inocras’ CancerVision™ and MRDVision™ Platforms in Phase 1/2 ATX-295 Clinical Study

On January 28, 2026 Inocras, a bioinformatics-led company harnessing the power of whole genome data and proprietary analytics to deliver curated insights, reported that Accent Therapeutics will deploy Inocras’ CancerVision and MRDVision whole genome platforms in its first-in-human Phase 1/2 dose-escalation study of ATX-295, a potential best-in-class inhibitor of the KIF18A protein.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Through this collaboration, Inocras’ CancerVision platform is being applied to characterize the detailed genomic status of clinical samples, while MRDVision provides ultra-sensitive monitoring of treatment response during dose escalation. Together, these platforms enable a comprehensive view of tumor dynamics.

"This collaboration marks an inflection point in how whole genome data drives clinical execution," said Jehee Suh, CEO of Inocras. "By deploying our CancerVision and MRDVision platforms, we are empowering Accent’s team with the comprehensive, ultra-sensitive insights needed to accelerate their groundbreaking ATX-295 program. This partnership underscores that whole genome profiling is no longer just for research; it is a critical tool for next-generation drug development."

"Access to a robust, clinically validated, whole-genome cancer profiling platform such as CancerVision has been critical to accelerating translational insights and clinical execution for our ATX-295 program," said Serena Silver, Ph.D., Chief Scientific Officer of Accent Therapeutics. "We are eager to use the insights gained from the Inocras platform to help advance ATX-295 in the clinic."

(Press release, Accent Therapeutics, JAN 28, 2026, View Source [SID1234662342])